Related Experiment Videos
Novel Ras antagonist blocks human melanoma growth
B Jansen1, H Schlagbauer-Wadl, H Kahr
1Department of Dermatology, Division of General Dermatology, University of Vienna, A-1090 Vienna, Austria. burkhard.jansen@univie.ac.at
Summary
S-trans, trans-farnesylthiosalicylic acid (FTS) effectively inhibits melanoma growth by targeting Ras signaling pathways. This novel Ras antagonist shows significant antitumor activity in vitro and in vivo, offering a potential new treatment for melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Advanced melanoma exhibits poor treatment response, partly due to activated N-Ras oncoproteins.
- Ras gene products are crucial in growth factor signaling, oncogenesis, and tumor progression in various human neoplasms, including melanoma.
Purpose of the Study:
- To evaluate the antitumor activity of S-trans, trans-farnesylthiosalicylic acid (FTS), a Ras antagonist.
- To investigate FTS's potential as a therapeutic agent for melanoma by targeting Ras activity.
Main Methods:
- In vitro and in vivo assessment of FTS in SCID mouse xenotransplantation models of human melanoma (wild-type Ras and activated Ras).
- Analysis of FTS effects on Ras isoforms, Ras-dependent signaling pathways (extracellular signal-regulated kinase), cell phenotype, and tumor growth.
Main Results:
- FTS reduced activated N-Ras and wild-type Ras levels in melanoma cells and fibroblasts.
- FTS inhibited melanoma cell growth in vitro, reversed transformed phenotypes, and significantly reduced tumor growth in vivo (82% for 518A2, 90% for 607B).
- No drug-related toxicity was observed in vivo.
Conclusions:
- FTS demonstrates significant antitumor activity against human melanoma models.
- FTS represents a novel and rational therapeutic approach for melanoma and potentially other tumors dependent on Ras signaling.